References
1. Wesevich A, Goldstein DA, Paydary K, Peer CJ, Figg WD, Ratain MJ.
Interventional pharmacoeconomics for immune checkpoint inhibitors
through alternative dosing strategies. British journal of cancer 2023.
2. Achini-Gutzwiller FR, Jol-van der Zijde CM, Jansen-Hoogendijk AM,
Lankester AC, Bredius RGM, van Tol MJD, Moes D, Schilham MW. Development
and Validation of an Efficient and Highly Sensitive Enzyme-Linked
Immunosorbent Assay for Alemtuzumab Quantification in Human Serum and
Plasma. Ther Drug Monit 2023; 45: 79-86.
3. Darrouzain F, Bian S, Desvignes C, Bris C, Watier H, Paintaud G, de
Vries A. Immunoassays for Measuring Serum Concentrations of Monoclonal
Antibodies and Anti-biopharmaceutical Antibodies in Patients. Ther Drug
Monit 2017; 39: 316-21.
4. Klaasen RA, Egeland EJ, Chan J, Midtvedt K, Svensson M, Bolstad N,
Fellstrom B, Holdaas H, Asberg A, Bergan S, Vethe NT, Warren DJ. A Fully
Automated Method for the Determination of Serum Belatacept and Its
Application in a Pharmacokinetic Investigation in Renal Transplant
Recipients. Ther Drug Monit 2019; 41: 11-18.
5. Suh K, Kyei I, Hage DS. Approaches for the detection and analysis of
antidrug antibodies to biopharmaceuticals: A review. J Sep Sci 2022; 45:
2077-92.
6. Todoroki K, Mizuno H, Sugiyama E, Toyo’oka T. Bioanalytical methods
for therapeutic monoclonal antibodies and antibody-drug conjugates: A
review of recent advances and future perspectives. J Pharm Biomed Anal
2020; 179: 112991.
7. Chhun S, Trauchessec M, Melicine S, Nicolas F, Miele A, Lukic S,
Vilain E, Amrouche L, Lebert D, Anglicheau D, Tartour E, Zuber J. A
Validated LC-MS/MS Method for Performing Belatacept Drug Monitoring in
Renal Transplantation. Biomedicines 2023; 11: 2955.
8. Mochizuki T, Shibata K, Naito T, Shimoyama K, Ogawa N, Maekawa M,
Kawakami J. LC-MS/MS method for the quantitation of serum tocilizumab in
rheumatoid arthritis patients using rapid tryptic digestion without IgG
purification. J Pharm Anal 2022; 12: 852-59.
9. Truffot A, Jourdil JF, Seitz-Polski B, Malvezzi P, Brglez V,
Stanke-Labesque F, Gautier-Veyret E. Simultaneous quantification of
rituximab and eculizumab in human plasma by liquid chromatography-tandem
mass spectrometry and comparison with rituximab ELISA kits. Clin Biochem
2021; 87: 60-66.
10. Willeman T, Jourdil JF, Gautier-Veyret E, Bonaz B, Stanke-Labesque
F. A multiplex liquid chromatography tandem mass spectrometry method for
the quantification of seven therapeutic monoclonal antibodies:
Application for adalimumab therapeutic drug monitoring in patients with
Crohn’s disease. Analytica chimica acta 2019; 1067: 63-70.
11. Richter WF, Bhansali SG, Morris ME. Mechanistic determinants of
biotherapeutics absorption following SC administration. The AAPS journal
2012; 14: 559-70.
12. Zou P. Predicting Human Bioavailability of Subcutaneously
Administered Fusion Proteins and Monoclonal Antibodies Using Human
Intravenous Clearance or Antibody Isoelectric Point. The AAPS journal
2023; 25: 31.
13. Liu L. Pharmacokinetics of monoclonal antibodies and Fc-fusion
proteins. Protein & cell 2018; 9: 15-32.
14. Baldwin WM, 3rd, Valujskikh A, Fairchild RL. The neonatal Fc
receptor: Key to homeostasic control of IgG and IgG-related
biopharmaceuticals. Am J Transplant 2019; 19: 1881-87.
15. Stern RM, Connell NT. Ravulizumab: a novel C5 inhibitor for the
treatment of paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol 2019;
10: 2040620719874728.
16. Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, Wine Y. The
Molecular Mechanisms That Underlie the Immune Biology of Anti-drug
Antibody Formation Following Treatment With Monoclonal Antibodies.
Frontiers in immunology 2020; 11: 1951.
17. Vaisman-Mentesh A, Rosenstein S, Yavzori M, Dror Y, Fudim E, Ungar
B, Kopylov U, Picard O, Kigel A, Ben-Horin S, Benhar I, Wine Y.
Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the
Immune Response Following Treatment With TNFα Antagonists. Frontiers in
immunology 2019; 10: 2921.
18. Kelly RL, Yu Y, Sun T, Caffry I, Lynaugh H, Brown M, Jain T, Xu Y,
Wittrup KD. Target-independent variable region mediated effects on
antibody clearance can be FcRn independent. mAbs 2016; 8: 1269-75.
19. Liu S, Shah DK. Physiologically Based Pharmacokinetic Modeling to
Characterize the Effect of Molecular Charge on Whole-Body Disposition of
Monoclonal Antibodies. The AAPS journal 2023; 25: 48.
20. Kantasiripitak W, Outtier A, Wicha SG, Kensert A, Wang Z, Sabino J,
Vermeire S, Thomas D, Ferrante M, Dreesen E. Multi-model averaging
improves the performance of model-guided infliximab dosing in patients
with inflammatory bowel diseases. CPT: pharmacometrics & systems
pharmacology 2022; 11: 1045-59.
21. Kantasiripitak W, Wicha SG, Thomas D, Hoffman I, Ferrante M,
Vermeire S, van Hoeve K, Dreesen E. A Model-Based Tool for Guiding
Infliximab Induction Dosing to Maximize Long-term Deep Remission in
Children with Inflammatory Bowel Diseases. Journal of Crohn’s & colitis
2023; 17: 896-908.
22. Strik AS, Löwenberg M, Mould DR, Berends SE, Ponsioen CI, van den
Brande JMH, Jansen JM, Hoekman DR, Brandse JF, Duijvestein M, Gecse KB,
de Vries A, Mathôt RA, D’Haens GR. Efficacy of dashboard driven dosing
of infliximab in inflammatory bowel disease patients; a randomized
controlled trial. Scand J Gastroenterol 2021; 56: 145-54.
23. Ternant D, Passot C, Aubourg A, Goupille P, Desvignes C, Picon L,
Lecomte T, Mulleman D, Paintaud G. Model-Based Therapeutic Drug
Monitoring of Infliximab Using a Single Serum Trough Concentration. Clin
Pharmacokinet 2017.
24. Mould DR, Baumann A, Kuhlmann J, Keating MJ, Weitman S, Hillmen P,
Brettman LR, Reif S, Bonate PL. Population
pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients
with chronic lymphocytic leukaemia and its link to treatment response.
Br J Clin Pharmacol 2007; 64: 278-91.
25. Pressly MA, Peletier LA, Zheng S, Sharma VD, Lien YTK, Wang W, Zhou
H, Schmidt S. The quest for balance between capturing data and model
complexity: A quantitative clinical pharmacology approach applied to
monoclonal antibodies. CPT: pharmacometrics & systems pharmacology
2023; 12: 639-55.
26. Jodele S, Mizuno K, Sabulski A, Vinks AA. Adopting Model-Informed
Precision-Dosing for Eculizumab in Transplant Associated-Thrombotic
Microangiopathy to Gene Therapies. Clin Pharmacol Ther 2023; 114:
511-14.
27. Mizuno K, Dandoy CE, Teusink-Cross A, Davies SM, Vinks AA, Jodele S.
Eculizumab precision-dosing algorithm for thrombotic microangiopathy in
children and young adults undergoing HSCT. Blood Adv 2022; 6: 1454-63.
28. de Graav GN, Bergan S, Baan CC, Weimar W, van Gelder T, Hesselink
DA. Therapeutic Drug Monitoring of Belatacept in Kidney Transplantation.
Therapeutic Drug Monitoring 2015; 37: 560-7.
29. Meesters-Ensing JI, Admiraal R, Ebskamp L, Lacna A, Boelens JJ,
Lindemans CA, Nierkens S. Therapeutic Drug Monitoring of Anti-Thymocyte
Globulin in Allogeneic Stem Cell Transplantation: Proof of Concept.
Frontiers in pharmacology 2022; 13: 828094.
30. van Vugt LK, Schagen MR, de Weerd A, Reinders ME, de Winter BC,
Hesselink DA. Investigational drugs for the treatment of kidney
transplant rejection. Expert Opin Investig Drugs 2022; 31: 1087-100.
31. Lorant T, Bengtsson M, Eich T, Eriksson BM, Winstedt L, Jarnum S,
Stenberg Y, Robertson AK, Mosen K, Bjorck L, Backman L, Larsson E, Wood
K, Tufveson G, Kjellman C. Safety, immunogenicity, pharmacokinetics, and
efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in
chronic kidney disease patients. Am J Transplant 2018.
32. Bertrand D, Brunel M, Lebourg L, Scemla A, Lemoine M, Amrouche L,
Laurent C, Legendre C, Guerrot D, Anglicheau D, Sberro-Soussan R.
Conversion From Intravenous In-Hospital Belatacept Injection to
Subcutaneous Abatacept Injection in Kidney Transplant Recipients During
the First COVID-19 Stay-at-Home Order in France. Transpl Int 2023; 36:
11328.
33. Medina F, Plasencia C, Goupille P, Ternant D, Balsa A, Mulleman D.
Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals
in Rheumatoid Arthritis. Ther Drug Monit 2017; 39: 364-69.
34. Genberg H, Hansson A, Wernerson A, Wennberg L, Tydén G.
Pharmacodynamics of rituximab in kidney allotransplantation. Am J
Transplant 2006; 6: 2418-28.
35. Sautenet B, Blancho G, Büchler M, Morelon E, Toupance O, Barrou B,
Ducloux D, Chatelet V, Moulin B, Freguin C, Hazzan M, Lang P, Legendre
C, Merville P, Mourad G, Mousson C, Pouteil-Noble C, Purgus R, Rerolle
JP, Sayegh J, Westeel PF, Zaoui P, Boivin H, Le Gouge A, Lebranchu Y.
One-year Results of the Effects of Rituximab on Acute Antibody-Mediated
Rejection in Renal Transplantation: RITUX ERAH, a Multicenter
Double-blind Randomized Placebo-controlled Trial. Transplantation 2016;
100: 391-9.
36. Mazilu D, Opriş D, Gainaru C, Iliuta M, Apetrei N, Luca G, Borangiu
A, Gudu T, Peltea A, Groseanu L, Constantinescu C, Saulescu I, Bojinca
V, Balanescu A, Predeteanu D, Ionescu R. Monitoring drug and antidrug
levels: a rational approach in rheumatoid arthritis patients treated
with biologic agents who experience inadequate response while being on a
stable biologic treatment. Biomed Res Int 2014; 2014: 702701.
37. Jäger U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G,
Burgstaller S, Mannhalter C, Oberaigner W, Porpaczy E, Skrabs C,
Einberger C, Drach J, Raderer M, Gaiger A, Putman M, Greil R. Rituximab
serum concentrations during immuno-chemotherapy of follicular lymphoma
correlate with patient gender, bone marrow infiltration and clinical
response. Haematologica 2012; 97: 1431-8.
38. Rozman S, Grabnar I, Novaković S, Mrhar A, Jezeršek Novaković B.
Population pharmacokinetics of rituximab in patients with diffuse large
B-cell lymphoma and association with clinical outcome. Br J Clin
Pharmacol 2017; 83: 1782-90.
39. Techa-Angkoon P, Siritho S, Tisavipat N, Suansanae T. Current
evidence of rituximab in the treatment of multiple sclerosis. Mult Scler
Relat Disord 2023; 75: 104729.
40. Zwart TC, Bezstarosti S, Achini FR, Reinders MEJ, Schilham MW, Heidt
S, Guchelaar HJ, de Fijter JW, Moes D. Population pharmacokinetics of
subcutaneous alemtuzumab in kidney transplantation. Br J Clin Pharmacol
2022.
41. Hullegie-Peelen DM, van der Zwan M, Clahsen-van Groningen MC,
Mustafa DAM, Baart SJ, Reinders MEJ, Baan CC, Hesselink DA. Clinical and
Molecular Profiling to Develop a Potential Prediction Model for the
Response to Alemtuzumab Therapy for Acute Kidney Transplant Rejection.
Clinical Pharmacology & Therapeutics 2022; n/a.
42. Hesselink DA, Hullegie-Peelen DM, van Vugt LK. Personalized
anti-rejection therapy with alemtuzumab for kidney transplant
recipients. Pharmacogenomics 2022; 23: 567-70.
43. Scalzo RE, Sanoff SL, Rege AS, Kwun J, Knechtle SJ, Barisoni L,
Byrns JS. Daratumumab Use Prior to Kidney Transplant and T Cell-Mediated
Rejection: A Case Report. American journal of kidney diseases : the
official journal of the National Kidney Foundation 2023; 81: 616-20.
44. Cabezas L, Jouve T, Malvezzi P, Janbon B, Giovannini D, Rostaing L,
Noble J. Tocilizumab and Active Antibody-Mediated Rejection in Kidney
Transplantation: A Literature Review. Frontiers in immunology 2022; 13:
839380.
45. January SE, Fester KA, Halverson LP, Witt CA, Byers DE,
Vazquez-Guillamet R, Alexander-Brett J, Tague LK, Kreisel D, Gelman A,
Puri V, Bahena RN, Takahashi T, Hachem RR, Kulkarni HS. Tocilizumab for
antibody-mediated rejection treatment in lung transplantation. The
Journal of heart and lung transplantation : the official publication of
the International Society for Heart Transplantation 2023; 42: 1353-57.
46. Miller CL, Madsen JC. IL-6 Directed Therapy in Transplantation.
Current transplantation reports 2021; 8: 191-204.
47. Weinhard J, Noble J, Jouve T, Malvezzi P, Rostaing L. Tocilizumab
and Desensitization in Kidney Transplant Candidates: Personal Experience
and Literature Review. J Clin Med 2021; 10.
48. Arrivé C, Jacquet M, Gautier-Veyret E, Jouve T, Noble J, Lombardo D,
Rostaing L, Stanke-Labesque F. Early Exposure of Kidney Transplant
Recipients with Chronic Antibody-Mediated Rejection to Tocilizumab-A
Preliminary Study. J Clin Med 2023; 12.
49. Massat M, Congy-Jolivet N, Hebral AL, Esposito L, Marion O, Delas A,
Colombat M, Faguer S, Kamar N, Del Bello A. Do anti-IL-6R blockers have
a beneficial effect in the treatment of antibody-mediated rejection
resistant to standard therapy after kidney transplantation? Am J
Transplant 2021; 21: 1641-49.
50. Tang ZC, Hui H, Shi C, Chen X. New findings in preventing recurrence
and improving renal function in AHUS patients after renal
transplantation treated with eculizumab: a systemic review and
meta-analyses. Renal failure 2023; 45: 2231264.
51. Coutance G, Kobashigawa JA, Kransdorf E, Loupy A, Desiré E,
Kittleson M, Patel JK. Intermediate-term outcomes of complement
inhibition for prevention of antibody-mediated rejection in
immunologically high-risk heart allograft recipients. The Journal of
heart and lung transplantation : the official publication of the
International Society for Heart Transplantation 2023; 42: 1464-68.
52. Kleiboeker HL, Prom A, Paplaczyk K, Myers CN. A Complement to
Traditional Treatments for Antibody-Mediated Rejection? Use of
Eculizumab in Lung Transplantation: A Review and Early Center
Experience. Ann Pharmacother 2023: 10600280231213112.